An Efficient Approach for the Synthesis of Panobinostat as Anti-Cancer Drug

Panobinostat is a drug developed by Novartis for the treatment of various cancers (Figure 1). It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan- HDAC inhibitor). Panobinostat inhibits multiple histone deacetylase enzymes, a mechanism leading to apoptosis of malignant cells via multiple pathways On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma who had received at least 2 previous treatments, including bortezomib and an immunomodulatory agent after clinical trials. We describe the synthesis of API of panobinostat and the effort made for new and different approaches to reach the most efficient way to produce it using suitable starting material. The details about the synthesis approach will be further discussed in the conference..